Bifogade filer
Kurs
+2,64%
Kalender
Est. tid* | ||
2024-02-29 | - | Bokslutskommuniké 2023 |
2023-11-23 | - | Kvartalsrapport 2023-Q3 |
2023-08-25 | - | Kvartalsrapport 2023-Q2 |
2023-06-30 | - | Årsstämma |
2023-05-31 | - | Kvartalsrapport 2023-Q1 |
2023-05-05 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
2023-02-28 | - | Bokslutskommuniké 2022 |
2023-02-09 | - | Extra Bolagsstämma 2022 |
2022-11-24 | - | Kvartalsrapport 2022-Q3 |
2022-08-26 | - | Kvartalsrapport 2022-Q2 |
2022-05-20 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
2022-05-19 | - | Årsstämma |
2022-05-11 | - | Kvartalsrapport 2022-Q1 |
2022-02-25 | - | Bokslutskommuniké 2021 |
2021-11-12 | - | Kvartalsrapport 2021-Q3 |
2021-07-16 | - | Kvartalsrapport 2021-Q2 |
2021-06-17 | - | Årsstämma |
2021-05-27 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
2021-05-07 | - | Kvartalsrapport 2021-Q1 |
2021-02-10 | - | Bokslutskommuniké 2020 |
2020-11-12 | - | Kvartalsrapport 2020-Q3 |
2020-07-17 | - | Kvartalsrapport 2020-Q2 |
2020-05-27 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
2020-05-26 | - | Årsstämma |
2020-05-15 | - | Kvartalsrapport 2020-Q1 |
2020-02-14 | - | Bokslutskommuniké 2019 |
2019-11-15 | - | Kvartalsrapport 2019-Q3 |
2019-08-19 | - | Extra Bolagsstämma 2019 |
2019-08-15 | - | Kvartalsrapport 2019-Q2 |
2019-05-31 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
2019-05-29 | - | Årsstämma |
2019-05-15 | - | Kvartalsrapport 2019-Q1 |
2019-02-28 | - | Bokslutskommuniké 2018 |
2018-11-30 | - | Kvartalsrapport 2018-Q3 |
2018-08-31 | - | Kvartalsrapport 2018-Q2 |
2018-06-14 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
2018-06-13 | - | Årsstämma |
2018-05-31 | - | Kvartalsrapport 2018-Q1 |
2018-02-28 | - | Bokslutskommuniké 2017 |
2017-11-28 | - | Kvartalsrapport 2017-Q3 |
2017-11-15 | - | Extra Bolagsstämma 2017 |
2017-08-31 | - | Kvartalsrapport 2017-Q2 |
2017-06-09 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
2017-06-08 | - | Årsstämma |
2017-05-31 | - | Kvartalsrapport 2017-Q1 |
2017-02-20 | - | Bokslutskommuniké 2016 |
2016-11-30 | - | Kvartalsrapport 2016-Q3 |
2016-08-31 | - | Kvartalsrapport 2016-Q2 |
2016-06-01 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
2016-05-31 | - | Årsstämma |
2016-05-31 | - | Kvartalsrapport 2016-Q1 |
2016-02-29 | - | Bokslutskommuniké 2015 |
2016-01-21 | - | Extra Bolagsstämma 2016 |
2015-11-30 | - | Kvartalsrapport 2015-Q3 |
2015-08-31 | - | Kvartalsrapport 2015-Q2 |
2015-06-12 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
2015-06-11 | - | Årsstämma |
2015-05-28 | - | Kvartalsrapport 2015-Q1 |
2015-02-27 | - | Bokslutskommuniké 2014 |
2014-11-28 | - | Kvartalsrapport 2014-Q3 |
2014-09-12 | - | Extra Bolagsstämma 2014 |
2014-08-29 | - | Kvartalsrapport 2014-Q2 |
2014-06-10 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
2014-06-09 | - | Årsstämma |
2014-05-23 | - | Kvartalsrapport 2014-Q1 |
2014-03-05 | - | Bokslutskommuniké 2013 |
2013-11-29 | - | Kvartalsrapport 2013-Q3 |
2013-09-04 | - | Kvartalsrapport 2013-Q2 |
2013-05-31 | - | Kvartalsrapport 2013-Q1 |
2013-05-08 | - | Split RLS 10:1 |
2013-04-11 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
2013-04-10 | - | Årsstämma |
2013-03-05 | - | Bokslutskommuniké 2012 |
2012-11-26 | - | Kvartalsrapport 2012-Q3 |
2012-08-31 | - | Kvartalsrapport 2012-Q2 |
2012-06-12 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
2012-06-11 | - | Årsstämma |
Beskrivning
Land | Sverige |
---|---|
Sektor | Hälsovård |
Industri | Medicinteknik |
- Net sales amounted to TSEK 219 (TSEK 139)
- Earnings before interest and taxes (EBIT) amounted to TSEK -7 478 (TSEK -7 655)
- Earning per share before dilution at SEK -0,11 (SEK -0,12)
- Cash flow from operating activities amounted to TSEK -4 887 (TSEK -7 000)
- Liquid assets at the end of the period TSEK 11 469 (TSEK 18 997)
- Equity ratio was 75 % (87 %).
JANUARY 1[st ]- DECEMBER 31[st] (previous year in brackets)
- Net sales amounted to TSEK 653 (TSEK 2 043)
- Earnings before interest and taxes (EBIT) amounted to TSEK -11 021 (TSEK -22 458)
- Earning per share before dilution at SEK -0,17 (SEK -0,34)
- Cash flow from operating activities amounted to TSEK -8 353 (TSEK -22 219)
- Liquid assets at the end of the period TSEK 11 469 (TSEK 18 997)
- Equity ratio was 75 % (87 %).
SUMMARY OF EVENTS DURING FOURTH QUARTER
- Activities in order to receive reimbursement in the European countries continue.
- The collaboration with ConvaTec is progressing according to plan and several training sessions have been completed together with RLS.
- The automatization project, aiming to lower the COGS of ChloraSolv and to secure
- RLS has received the first order for ChloraSolv from ConvaTec.
- RLS received a guaranteed bridgeloan from one of the main owners.
- As throughout the year 2021, during the fourth quarter it has been challenging to arrange physical meetings with the healthcare sector. We look forward to meeting customers physically again.
TRADING PLACE AND CERTIFIED ADVISER
RLS Global's shares have been listed on the Nasdaq First North Growth Market since 17[th] May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag, phone: +46 8 121 576 90, email: certifiedadviser@redeye.se.During the period 2012-2017, the company was listed on Aktietorget.
The Year-end Report Q4, 2021, is enclosed and is also available here:
https://rls.global/wp-content/uploads/2022/02/RLS_Global_Q4_2021_EN.pdf
PUBLICATION
This information was submitted for publication through the agency of the below contact person, at 09.00 CET on Feb 25[th] 2022.
Karin Fischer, CEO
E-mail: karin.fischer@rlsglobal.se
Telephone: +46 702-48 46 51
Eva Jagenheim, CFO
E-mail: eva.jagenheim@rlsglobal.se
Telephone: +46 31 780 68 20